Charting of immune reactivity against HPV in patients with HPV-induced (pre-) malignant lesions: The Circle study "2"

Charting of immune reactivity against HPV in patients with HPV-induced (pre-) malignant lesions: The Circle study "2" - The Circle Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47408

Enrollment

1000

Registered

2009-02-05

Start date

2009-02-05

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer HPV-induced malignancies

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: HPV-related infection or HPV-related anogenital and/or cervical premalignant lesion, or HPV-related carcinoma

Exclusion criteria

Exclusion criteria: Younger than 18 years Non-HPV related disease

Design outcomes

Primary

Measure	Time frame
The presence, number, phenotype and function of both circulating (blood) and locally present (lesion/tumor/lymph node) HPV-specific immune cells under several conditions will be measured by the use of ELISPOT, proliferation, cytokine production by bead array, CFSE based suppression assays, cytotoxicity assays, multi-parameter flow cytometry and ELISA.	—

Secondary

Measure	Time frame
The secondary objectives of this study are to assess: - The linkage between immunity-related genetic variation and disease susceptibility. - Clinical responsiveness and HPV-specific immunity. - Influence of therapy on HPV-specific immunity and vice verse. - Factors influencing tissue-infiltration by different populations of (HPV-specific) immune cells. - The possibility to specifically expand defined populations of HPV-specific immune cells.	—

Measure

Time frame

The secondary objectives of this study are to assess: - The linkage between immunity-related genetic variation and disease susceptibility. - Clinical responsiveness and HPV-specific immunity. - Influence of therapy on HPV-specific immunity and vice verse. - Factors influencing tissue-infiltration by different populations of (HPV-specific) immune cells. - The possibility to specifically expand defined populations of HPV-specific immune cells.

—

Countries

Netherlands

Outcome results